Warning: fopen(/home/virtual/colon/journal/upload/ip_log/ip_log_2024-11.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96
1Department of Surgery, Yonsei University Wonju College of Medicine, Wonju, Korea
2Division of Gastroenterology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea
3Department of Surgery, Konkuk University Chungju Hospital, Chungju, Korea
4Department of Anesthesiology, Yonsei University Wonju College of Medicine, Wonju, Korea
5Department of Family Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea
Copyright © 2022 The Korean Society of Coloproctology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was reported.
Marker | Year | Main outcome | Study | N | Design, center | Surgical disease | TNM stage | Cut-off | Therapy | Statistics and comments |
---|---|---|---|---|---|---|---|---|---|---|
NLR | 2020 | Postoperative complications OS DFS | Xia et al. [37] | 154 | Retrospective, single center | RC | T1–2 | 2.8 | Resection | NLR was associated with postoperative CTx. |
NLR was an independent prognostic factor for DFS (HR, 6.656, P = 0.009). | ||||||||||
NLR | 2019 | Ileostomy amount: 2,000 mL/day | Hiramoto et al. [43] | 45 | Retrospective, single center | CRC | 1–4 | 3.0 | Resection | Preoperative NLR was significantly higher in the high-output ileostomy group (P = 0.004). |
NLR | 2019 | OS DFS | Kim et al. [48] | 83 | Retrospective, 2 centers | CRLM | 4 | 1.94 | Resection, CTx | HR, 2.23; independent prognostic factor |
NLR | 2019 | pCR OS | Mao et al. [49] | 183 | Retrospective, single center | CRLM | 4 | 2.3 | Preoperative CTx, resection | OR, 2.40; P = 0.015 |
RFS | HR, 2.43; P < 0.001 | |||||||||
HR, 1.53; P = 0.017 | ||||||||||
NLR | 2019 | OS PFS | Casadei-Gardini et al. [51] | 276 | RCT, multi-center | mCRC | 4 | 3 | CTx (± bevacizumab) | HR, 2.38 |
HR, 2.27 | ||||||||||
NLR + LDH is a good prognostic marker for mCRC with 1st-line CTx. | ||||||||||
NLR | 2016 | OS | Ishizuka et al. [77] | 627 | Retrospective, single center | CRC | 1–4 | 2.9 | Resection | HR, 1.811; P = 0.003 |
NLR | 2016 | OS | Shibutani et al. [50] | 99 | Retrospective, single center | Unresectable mCRC | 4 | 3 | Palliative CTx | HR, 2.706; P = 0.001 |
NLR | 2016 | Tumor regression grade | Caputo et al. [42] | 151 | Retrospective, single center | RC | 2, 3 | 2.8 | nCRT followed by total mesorectal excision | Preoperative high NLR was associated with overall postoperative complications. |
Postoperative complications | ||||||||||
NLR | 2014 | pCR | Kim et al. [46] | 102 | Retrospective, single center | CRC | 1–4 | 3 | Preoperative CRT, resection | HR, 5.2; P = 0.04 |
CSS | HR, 6.6; P = 0.02 | |||||||||
RFS | HR, 2.8; P = 0.03 | |||||||||
NLR | 2014 | OS | Neofytou et al. [56] | 140 | Retrospective, single center | CRLM | 4 | 2.4 | Resection | NLR was not an independent prognostic factor for OS or DFS. |
DFS | ||||||||||
NLR | 2014 | Hospital LOS | Gohil et al. [41] | 196 | Retrospective, single center | CRC | 1–4 | 4.3 | Resection | Preoperative NLR was associated with increased LOS (OR, 1.702). |
NLR, neutrophil-lymphocyte ratio; OS, overall survival; DFS, disease-free survival; RC, rectal cancer; CTx, chemotherapy; HR, hazard ratio; CRC, colorectal cancer; CRLM, colorectal cancer with liver metastasis; pCR, pathologic complete response; RFS, relapse-free survival; OR, odds ratio; PFS, progression-free survival; RCT, randomized controlled trial; mCRC, metastatic colorectal cancer; LDH, lactate dehydrogenase; FOLFIRI, folinic acid, fluorouracil, and irinotecan; nCRT, neoadjuvant chemoradiotherapy; CSS, cancer-specific survival; LOS, length of stay.
Marker | Year | Main outcome | Author | N | Design, center | Surgical disease | TNM stage | Cut-off | Therapy | Statistics and comments |
---|---|---|---|---|---|---|---|---|---|---|
PLT | 2018 | pCR | Belluco et al. [35] | 965 | Retrospective, multicenter | RC with nCRT | 2, 3 | 300K | nCRT followed by TME | OR, 0.51; P=0.001 |
OS | HR, 1.45; P=0.009 | |||||||||
DFS | HR, 1.39; P=0.009 | |||||||||
PLT | 2012 | OS | Ishizuka et al. [36] | 453 | Retrospective, single center | CRC | 1–4 | 300K | Resection | OR, 1.642; P=0.039 |
Thrombocytosis is associated with OS. | ||||||||||
PLR | 2020 | Postoperative complication | Xia et al. [37] | 154 | Retrospective, single center | RC | T1–2 | 140.0 | Resection | PLR was associated with postoperative complications. However, PLR was not an independent prognostic factor for OS, DFS. |
OS | ||||||||||
DFS | ||||||||||
PLR | 2015 | CSS | Ozawa et al. [54] | 234 | Retrospective, single center | CRC | 2 | 25.4 | Resection | HR, 3.61; P=0.038 |
DFS | HR, 2.65; P=0.011 | |||||||||
PLR | 2014 | OS | Neofytou et al. [56] | 140 | Retrospective, single center | CRLM | 4 | 15 | Resection | HR, 2.17; P=0.027 |
DFS | HR, 1.68; P=0.034 |
PLT, platelet; OS, overall survival; DFS, disease-free survival; RC, rectal cancer; pCR, pathologic complete response; nCRT, neoadjuvant chemoradiotherapy; TME, total mesorectal excision; OR, odds ratio; HR, hazard ratio; CSS, cancer-specific survival; CRC, colorectal cancer; PLR, platelet-to-lymphocyte ratio; CRLM, colorectal cancer with liver metastasis.
Marker | Year | Main outcome | Author | N | Design, center | Surgical disease | TNM stage | Cut-off | Therapy | Statistics and comments |
---|---|---|---|---|---|---|---|---|---|---|
Alb | 2019 | OS | Yamamoto et al. [64] | 523 | Retrospective, single center | CRC | 1–4 | 3.85 | Resection | Kaplan-Meier test, P < 0.0001 |
DFS | ||||||||||
ΔAlba | 2018 | Postoperative complication | Wang et al. [63] | 193 | Retrospective, single center | CRC | 1–3 | 17.3% | Resection | OR, 1.66/+ |
Alb | 2017 | Postoperative morbidity, mortality | Chiang et al. [61] | 3,732 | Retrospective, single center | CC | 1–3 | 3.5 | Resection | OR, 0.927 |
OR, 0.844 | ||||||||||
Morbidity and mortality were inversely related to Alb. | ||||||||||
Alb | 2015 | 30-Day mortality | Montomoli et al. [62] | 9,339 | Prospective, population-based cohort | CRC | 1–4 | 2.5 | Resection | HR, 7.59 |
2.6–3.0 | HR, 5.19 | |||||||||
3.1–3.5 | HR, 2.58 | |||||||||
3.6–4.0 4.0 | HR, 1.75 | |||||||||
HR, 1.00 | ||||||||||
Preoperative Alb was inversely associated with 30-day mortality. | ||||||||||
Alb | 2014 | Hospital LOS | Gohil et al. [41] | 196 | Retrospective, single center | CRC | 1–4 | 34.5 g/dL | Resection | OR, 0.47/+ |
Alb | 2011 | Short-term outcomes | Lai et al. [65] | 3,849 | Retrospective, single center | CC | 1–3 | 3.5 | Resection | OR, 2.15; P < 0.001 |
OS | HR, 1.75; P < 0.001 | |||||||||
RFS | HR, 1.28; P = 0.020 | |||||||||
Alb | 2009 | OS | Sun et al. [66] | 1,367 | Retrospective, single center | CRC | 1–4 | 3.5 | Resection | HR, 1.45; P = 0.011 |
CSS | Alb was associated only with CSS. | |||||||||
CRP | 2017 | PFS | Artaç et al. [52] | 90 | Retrospective, 2 centers | mCRC | 4 | ULN | Bevacizumab + FOLFIRI | Only CRP was confirmed to be associated with PFS in the multivariate analysis. |
CRP | 2008 | CSS | Koike et al. [70] | 300 | Retrospective, single center | CRC | 1, 2 | 0.5 mg/dL | Resection | HR, 1.88/+ |
GPS | 2016 | OS | Ishizuka et al. [77] | 627 | Retrospective, single center | CRC | 1–4 | 0, 1, 2 | Resection | HR, 1.809; P = 0.006 |
mGPS | 2009 | Postoperative infection | Moyes et al. [76] | 455 | Retrospective, single center | CRC | 1–3 | 0, 1, 2 | Resection | HR, 1.76; P = 0.003 |
mGPS | 2007 | OS (3 yr) | McMillan et al. [74] | 316 | Retrospective, single center | CRC | 1–3 | 0, 1, 2 | Resection | Univariate analysis/+ |
CSS (3 yr) | ||||||||||
CAR | 2017 | Postoperative complication | Ge et al. [81] | 359 | Retrospective, single center | CRC | 1–3 | 0.022 | Resection | OR, 4.413; P < 0.001 |
CAR | 2017 | OS | Haruki et al. [84] | 112 | Retrospective, single center | CRLM | 4 | 0.04 | Resection | HR, 2.559; P = 0.021 |
DFS | HR, 1.731; P = 0.002 | |||||||||
CAR | 2017 | OS DFS | Ide et al. [83] | 115 | Retrospective, single center | RC with nCRT | 1–3 | 0.049 | nCRT followed by TME | HR, 5.09; P < 0.01 |
HR, 4.98; P < 0.01 | ||||||||||
CAR | 2016 | RFS | Shibutani et al. [85] | 705 | Retrospective, single center | CRC | 1–3 | 0.0271 | Resection | HR, 1.503/+ |
CSS | HR, 1.672/+ | |||||||||
CAR | 2016 | OS | Ishizuka et al. [77] | 627 | Retrospective, single center | CRC | 1–4 | 0.038 | Resection | HR, 2.613; P < 0.001 |
CAR | 2016 | OS | Shibutani et al. [50] | 99 | Retrospective, single center | Unresectable mCRC | 4 | 0.183 | Palliative CTx | HR, 1.866; P = 0.031 |
CAR | 2016 | Side effects (G3 or G4) | Tominaga et al. [82] | 136 | Retrospective, single center | CRC | 3 | 0.1 | Adjuvant CTx | HR, 7.06; P < 0.001 |
GAR | 2018 | OS | Hachiya et al. [87] | 941 | Retrospective, single center | CRC | 1–4 | 0.83 | Resection | HR, 1.979; P=0.001 |
NLR was also associated with OS. | ||||||||||
AGR | 2015 | OS | Shibutani et al. [88] | 66 | Retrospective, single center | Unresectable mCRC | 4 | 1.25 | CTx | HR, 2.247 |
PFS | HR, 2.662 | |||||||||
The high-AGR group showed superior chemotherapeutic response | ||||||||||
AGR | 2013 | OS | Azab et al. [89] | 534 | Retrospective, single center | CRC | 1–4 | < 1.029 | Resection, CTx | High AGR was associated with improved survival (HR, 0.25). |
1.028–1.321 | ||||||||||
> 1.321 | ||||||||||
LCR | 2020 | Postoperative complication (SSI) | Okugawa et al. [90] | 477 | Retrospective, 2 centers | CRC | 1–4 | 6,000 | Resection | Low LCR was associated with postoperative complication and survival. |
OS | ||||||||||
DFS |
Alb, albumin; OS, overall survival; DFS, disease-free survival; CRC, colorectal cancer; OR, odds ratio; CC, colon cancer; HR, hazard ratio; LOS, length of stay; RFS, relapse-free survival; CSS, cancer-specific survival; PFS, progression-free survival; mCRC, metastatic CRC; ULN, upper limit of normal; FOLFIRI, folinic acid, fluorouracil and irinotecan; CRP, C-reactive protein; GPS, Glasgow Prognostic Score; mGPS, modified GPS; CAR, CRP-albumin ratio; CRLM, colorectal cancer with liver metastasis; RC, rectal cancer; nCRT, neoadjuvant chemoradiotherapy; TME, total mesorectal excision; CTx, chemotherapy; GAR, globulin-albumin ration; AGR, albumin-globulin ration; SSI, surgical site infection; LCR, lymphocyte-CRP ratio.
a(Preoperative Alb−Alb at postoperative day 2)/preoperative Alb.
Disease and serologic test | Short-term outcome | Overall survival | Disease-freesurvival | Progression-free survival |
---|---|---|---|---|
Colon cancer | ||||
CBC | ||||
Chemistry | Alb [61, 65] | Alb [65] | Alb [65] | |
Rectal cancer | ||||
CBC | NLR, PLR [37] | PLT [35] | NLR [37] | |
NLR [42] | PLT [35] | |||
Chemistry | CAR [83] | CAR [83] | ||
Colorectal cancer | ||||
CBC | NLR [41] | PLT [36], NLR [46] | NLR [46] | |
CAR [77] | ||||
Chemistry | Alb, NLR [41] | Alb [64] | Alb [64] | |
Alb [62, 63] | GPS [74] | LCR [90] | ||
mGPS [76] | CAR [77] | |||
LCR [90] | GAR [87] | |||
LCR [90] | ||||
Metastatic colorectal cancer | ||||
CBC | NLR [48-51] | NLR [48, 49] | NLR [51, 52] | |
PLR [56] | PLR [56] | |||
Chemistry | CAR [50] | CAR [84] | CRP [52] | |
CAR [84] | AGR [88] | |||
AGR [88] |
CBC, complete blood count; Alb, albumin; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; PLT, platelet; CAR, CRP-albumin ratio; mGPS, modified GPS; GPS, Glasgow Prognostic Score; GAR, globulin-albumin ration; LCR, lymphocyte-CRP ratio; AGR, albumin-globulin ration; CRP, C-reactive protein.
Marker | Year | Main outcome | Study | N | Design, center | Surgical disease | TNM stage | Cut-off | Therapy | Statistics and comments |
---|---|---|---|---|---|---|---|---|---|---|
NLR | 2020 | Postoperative complications OS DFS | Xia et al. [37] | 154 | Retrospective, single center | RC | T1–2 | 2.8 | Resection | NLR was associated with postoperative CTx. |
NLR was an independent prognostic factor for DFS (HR, 6.656, P = 0.009). | ||||||||||
NLR | 2019 | Ileostomy amount: 2,000 mL/day | Hiramoto et al. [43] | 45 | Retrospective, single center | CRC | 1–4 | 3.0 | Resection | Preoperative NLR was significantly higher in the high-output ileostomy group (P = 0.004). |
NLR | 2019 | OS DFS | Kim et al. [48] | 83 | Retrospective, 2 centers | CRLM | 4 | 1.94 | Resection, CTx | HR, 2.23; independent prognostic factor |
NLR | 2019 | pCR OS | Mao et al. [49] | 183 | Retrospective, single center | CRLM | 4 | 2.3 | Preoperative CTx, resection | OR, 2.40; P = 0.015 |
RFS | HR, 2.43; P < 0.001 | |||||||||
HR, 1.53; P = 0.017 | ||||||||||
NLR | 2019 | OS PFS | Casadei-Gardini et al. [51] | 276 | RCT, multi-center | mCRC | 4 | 3 | CTx (± bevacizumab) | HR, 2.38 |
HR, 2.27 | ||||||||||
NLR + LDH is a good prognostic marker for mCRC with 1st-line CTx. | ||||||||||
NLR | 2016 | OS | Ishizuka et al. [77] | 627 | Retrospective, single center | CRC | 1–4 | 2.9 | Resection | HR, 1.811; P = 0.003 |
NLR | 2016 | OS | Shibutani et al. [50] | 99 | Retrospective, single center | Unresectable mCRC | 4 | 3 | Palliative CTx | HR, 2.706; P = 0.001 |
NLR | 2016 | Tumor regression grade | Caputo et al. [42] | 151 | Retrospective, single center | RC | 2, 3 | 2.8 | nCRT followed by total mesorectal excision | Preoperative high NLR was associated with overall postoperative complications. |
Postoperative complications | ||||||||||
NLR | 2014 | pCR | Kim et al. [46] | 102 | Retrospective, single center | CRC | 1–4 | 3 | Preoperative CRT, resection | HR, 5.2; P = 0.04 |
CSS | HR, 6.6; P = 0.02 | |||||||||
RFS | HR, 2.8; P = 0.03 | |||||||||
NLR | 2014 | OS | Neofytou et al. [56] | 140 | Retrospective, single center | CRLM | 4 | 2.4 | Resection | NLR was not an independent prognostic factor for OS or DFS. |
DFS | ||||||||||
NLR | 2014 | Hospital LOS | Gohil et al. [41] | 196 | Retrospective, single center | CRC | 1–4 | 4.3 | Resection | Preoperative NLR was associated with increased LOS (OR, 1.702). |
Marker | Year | Main outcome | Author | N | Design, center | Surgical disease | TNM stage | Cut-off | Therapy | Statistics and comments |
---|---|---|---|---|---|---|---|---|---|---|
PLT | 2018 | pCR | Belluco et al. [35] | 965 | Retrospective, multicenter | RC with nCRT | 2, 3 | 300K | nCRT followed by TME | OR, 0.51; P=0.001 |
OS | HR, 1.45; P=0.009 | |||||||||
DFS | HR, 1.39; P=0.009 | |||||||||
PLT | 2012 | OS | Ishizuka et al. [36] | 453 | Retrospective, single center | CRC | 1–4 | 300K | Resection | OR, 1.642; P=0.039 |
Thrombocytosis is associated with OS. | ||||||||||
PLR | 2020 | Postoperative complication | Xia et al. [37] | 154 | Retrospective, single center | RC | T1–2 | 140.0 | Resection | PLR was associated with postoperative complications. However, PLR was not an independent prognostic factor for OS, DFS. |
OS | ||||||||||
DFS | ||||||||||
PLR | 2015 | CSS | Ozawa et al. [54] | 234 | Retrospective, single center | CRC | 2 | 25.4 | Resection | HR, 3.61; P=0.038 |
DFS | HR, 2.65; P=0.011 | |||||||||
PLR | 2014 | OS | Neofytou et al. [56] | 140 | Retrospective, single center | CRLM | 4 | 15 | Resection | HR, 2.17; P=0.027 |
DFS | HR, 1.68; P=0.034 |
Marker | Year | Main outcome | Author | N | Design, center | Surgical disease | TNM stage | Cut-off | Therapy | Statistics and comments |
---|---|---|---|---|---|---|---|---|---|---|
Alb | 2019 | OS | Yamamoto et al. [64] | 523 | Retrospective, single center | CRC | 1–4 | 3.85 | Resection | Kaplan-Meier test, P < 0.0001 |
DFS | ||||||||||
ΔAlb |
2018 | Postoperative complication | Wang et al. [63] | 193 | Retrospective, single center | CRC | 1–3 | 17.3% | Resection | OR, 1.66/+ |
Alb | 2017 | Postoperative morbidity, mortality | Chiang et al. [61] | 3,732 | Retrospective, single center | CC | 1–3 | 3.5 | Resection | OR, 0.927 |
OR, 0.844 | ||||||||||
Morbidity and mortality were inversely related to Alb. | ||||||||||
Alb | 2015 | 30-Day mortality | Montomoli et al. [62] | 9,339 | Prospective, population-based cohort | CRC | 1–4 | 2.5 | Resection | HR, 7.59 |
2.6–3.0 | HR, 5.19 | |||||||||
3.1–3.5 | HR, 2.58 | |||||||||
3.6–4.0 4.0 | HR, 1.75 | |||||||||
HR, 1.00 | ||||||||||
Preoperative Alb was inversely associated with 30-day mortality. | ||||||||||
Alb | 2014 | Hospital LOS | Gohil et al. [41] | 196 | Retrospective, single center | CRC | 1–4 | 34.5 g/dL | Resection | OR, 0.47/+ |
Alb | 2011 | Short-term outcomes | Lai et al. [65] | 3,849 | Retrospective, single center | CC | 1–3 | 3.5 | Resection | OR, 2.15; P < 0.001 |
OS | HR, 1.75; P < 0.001 | |||||||||
RFS | HR, 1.28; P = 0.020 | |||||||||
Alb | 2009 | OS | Sun et al. [66] | 1,367 | Retrospective, single center | CRC | 1–4 | 3.5 | Resection | HR, 1.45; P = 0.011 |
CSS | Alb was associated only with CSS. | |||||||||
CRP | 2017 | PFS | Artaç et al. [52] | 90 | Retrospective, 2 centers | mCRC | 4 | ULN | Bevacizumab + FOLFIRI | Only CRP was confirmed to be associated with PFS in the multivariate analysis. |
CRP | 2008 | CSS | Koike et al. [70] | 300 | Retrospective, single center | CRC | 1, 2 | 0.5 mg/dL | Resection | HR, 1.88/+ |
GPS | 2016 | OS | Ishizuka et al. [77] | 627 | Retrospective, single center | CRC | 1–4 | 0, 1, 2 | Resection | HR, 1.809; P = 0.006 |
mGPS | 2009 | Postoperative infection | Moyes et al. [76] | 455 | Retrospective, single center | CRC | 1–3 | 0, 1, 2 | Resection | HR, 1.76; P = 0.003 |
mGPS | 2007 | OS (3 yr) | McMillan et al. [74] | 316 | Retrospective, single center | CRC | 1–3 | 0, 1, 2 | Resection | Univariate analysis/+ |
CSS (3 yr) | ||||||||||
CAR | 2017 | Postoperative complication | Ge et al. [81] | 359 | Retrospective, single center | CRC | 1–3 | 0.022 | Resection | OR, 4.413; P < 0.001 |
CAR | 2017 | OS | Haruki et al. [84] | 112 | Retrospective, single center | CRLM | 4 | 0.04 | Resection | HR, 2.559; P = 0.021 |
DFS | HR, 1.731; P = 0.002 | |||||||||
CAR | 2017 | OS DFS | Ide et al. [83] | 115 | Retrospective, single center | RC with nCRT | 1–3 | 0.049 | nCRT followed by TME | HR, 5.09; P < 0.01 |
HR, 4.98; P < 0.01 | ||||||||||
CAR | 2016 | RFS | Shibutani et al. [85] | 705 | Retrospective, single center | CRC | 1–3 | 0.0271 | Resection | HR, 1.503/+ |
CSS | HR, 1.672/+ | |||||||||
CAR | 2016 | OS | Ishizuka et al. [77] | 627 | Retrospective, single center | CRC | 1–4 | 0.038 | Resection | HR, 2.613; P < 0.001 |
CAR | 2016 | OS | Shibutani et al. [50] | 99 | Retrospective, single center | Unresectable mCRC | 4 | 0.183 | Palliative CTx | HR, 1.866; P = 0.031 |
CAR | 2016 | Side effects (G3 or G4) | Tominaga et al. [82] | 136 | Retrospective, single center | CRC | 3 | 0.1 | Adjuvant CTx | HR, 7.06; P < 0.001 |
GAR | 2018 | OS | Hachiya et al. [87] | 941 | Retrospective, single center | CRC | 1–4 | 0.83 | Resection | HR, 1.979; P=0.001 |
NLR was also associated with OS. | ||||||||||
AGR | 2015 | OS | Shibutani et al. [88] | 66 | Retrospective, single center | Unresectable mCRC | 4 | 1.25 | CTx | HR, 2.247 |
PFS | HR, 2.662 | |||||||||
The high-AGR group showed superior chemotherapeutic response | ||||||||||
AGR | 2013 | OS | Azab et al. [89] | 534 | Retrospective, single center | CRC | 1–4 | < 1.029 | Resection, CTx | High AGR was associated with improved survival (HR, 0.25). |
1.028–1.321 | ||||||||||
> 1.321 | ||||||||||
LCR | 2020 | Postoperative complication (SSI) | Okugawa et al. [90] | 477 | Retrospective, 2 centers | CRC | 1–4 | 6,000 | Resection | Low LCR was associated with postoperative complication and survival. |
OS | ||||||||||
DFS |
Disease and serologic test | Short-term outcome | Overall survival | Disease-freesurvival | Progression-free survival |
---|---|---|---|---|
Colon cancer | ||||
CBC | ||||
Chemistry | Alb [61, 65] | Alb [65] | Alb [65] | |
Rectal cancer | ||||
CBC | NLR, PLR [37] | PLT [35] | NLR [37] | |
NLR [42] | PLT [35] | |||
Chemistry | CAR [83] | CAR [83] | ||
Colorectal cancer | ||||
CBC | NLR [41] | PLT [36], NLR [46] | NLR [46] | |
CAR [77] | ||||
Chemistry | Alb, NLR [41] | Alb [64] | Alb [64] | |
Alb [62, 63] | GPS [74] | LCR [90] | ||
mGPS [76] | CAR [77] | |||
LCR [90] | GAR [87] | |||
LCR [90] | ||||
Metastatic colorectal cancer | ||||
CBC | NLR [48-51] | NLR [48, 49] | NLR [51, 52] | |
PLR [56] | PLR [56] | |||
Chemistry | CAR [50] | CAR [84] | CRP [52] | |
CAR [84] | AGR [88] | |||
AGR [88] |
NLR, neutrophil-lymphocyte ratio; OS, overall survival; DFS, disease-free survival; RC, rectal cancer; CTx, chemotherapy; HR, hazard ratio; CRC, colorectal cancer; CRLM, colorectal cancer with liver metastasis; pCR, pathologic complete response; RFS, relapse-free survival; OR, odds ratio; PFS, progression-free survival; RCT, randomized controlled trial; mCRC, metastatic colorectal cancer; LDH, lactate dehydrogenase; FOLFIRI, folinic acid, fluorouracil, and irinotecan; nCRT, neoadjuvant chemoradiotherapy; CSS, cancer-specific survival; LOS, length of stay.
PLT, platelet; OS, overall survival; DFS, disease-free survival; RC, rectal cancer; pCR, pathologic complete response; nCRT, neoadjuvant chemoradiotherapy; TME, total mesorectal excision; OR, odds ratio; HR, hazard ratio; CSS, cancer-specific survival; CRC, colorectal cancer; PLR, platelet-to-lymphocyte ratio; CRLM, colorectal cancer with liver metastasis.
Alb, albumin; OS, overall survival; DFS, disease-free survival; CRC, colorectal cancer; OR, odds ratio; CC, colon cancer; HR, hazard ratio; LOS, length of stay; RFS, relapse-free survival; CSS, cancer-specific survival; PFS, progression-free survival; mCRC, metastatic CRC; ULN, upper limit of normal; FOLFIRI, folinic acid, fluorouracil and irinotecan; CRP, C-reactive protein; GPS, Glasgow Prognostic Score; mGPS, modified GPS; CAR, CRP-albumin ratio; CRLM, colorectal cancer with liver metastasis; RC, rectal cancer; nCRT, neoadjuvant chemoradiotherapy; TME, total mesorectal excision; CTx, chemotherapy; GAR, globulin-albumin ration; AGR, albumin-globulin ration; SSI, surgical site infection; LCR, lymphocyte-CRP ratio. (Preoperative Alb−Alb at postoperative day 2)/preoperative Alb.
CBC, complete blood count; Alb, albumin; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; PLT, platelet; CAR, CRP-albumin ratio; mGPS, modified GPS; GPS, Glasgow Prognostic Score; GAR, globulin-albumin ration; LCR, lymphocyte-CRP ratio; AGR, albumin-globulin ration; CRP, C-reactive protein.